Trials / Completed
CompletedNCT00048516
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paricalcitol capsule |
Timeline
- Start date
- 2002-02-01
- First posted
- 2002-11-04
- Last updated
- 2006-08-02
Locations
18 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00048516. Inclusion in this directory is not an endorsement.